{"composite_breakdown_label":"","computation_units":"","copyright":"","data_footnote":"","data_non_statistical":false,"data_notice_class":"","data_notice_heading":"","data_notice_text":"","data_show_map":false,"data_start_values":[{"field":"Vacuna","value":"SH_ACS_DTP3"},{"field":"Vacuna","value":"SH_ACS_PCV3"},{"field":"Vacuna","value":"SH_ACS_MCV2"},{"field":"Vacuna","value":"SH_ACS_HPV"}],"embedded_feature_footer":"","embedded_feature_html":"","embedded_feature_tab_title":"","embedded_feature_title":"","embedded_feature_url":"","expected_disaggregations":[],"graph_annotations":[],"graph_limits":[],"graph_stacked_disaggregation":"","graph_title":"global_indicators.3-b-1-title","graph_titles":[],"graph_type":"line","indicator_name":"global_indicators.3-b-1-title","indicator_number":"3.b.1","national_geographical_coverage":"","page_content":"GRAFICO.3-b-1-contenido","permalink":"","precision":[],"progress_status":"retroceso","reporting_status":"complete","sort":"","sources":[{"organisation":"FUENTE.GE_Sanidad","periodicity":"FUENTE.FREQ_A","url":"FUENTE.GE_Sanidad_evs_url","url_text":"FUENTE.GE_Sanidad_evs","logo":"FUENTE.GE_logo"}],"standalone":false,"tags":[],"indicador_disponible":"global_indicators.3-b-1-title","objetivo_global":"objetivo_largo.3-titulo","meta_global":"meta_largo.3-b-titulo","definicion":"Programa nazional bakoitzean sartutako txerto guztiekin immunizatutako biztanleriaren proportzioa","formula":"\n$$PPV_{\\text{txertoa}}^{t} = \\frac{PV_{\\text{txertoa}}^{\\text{kohortea}\\, t - c}}{P^{\\text{kohortea}\\, t - c}} \\cdot 100$$\n\nnon:\n\n$PV_{\\text{txertoa}}^{\\text{kohortea}\\, t - c}=$ zehaztutako txerto motaren bidez txertatutako biztanleria, $t-c$-an jaiotako kohorteari dagokiona\n\n$P^{\\text{kohortea}\\, t - c}=$ $t-c$-an jaiotako kohortearen biztanleria osoa\n\n${c}=$ txerto bakoitzerako kohorte espezifikoa definitzen duen urte-tartea (c = 1 edo t-1ean jaiotako kohortea DTPa eta VNCrako, c = 5 SRPrako eta c = 13 VPHrako)\n","desagregacion":"Txerto mota\n","periodicidad":"FUENTE.FREQ_A","observaciones":"\nEmandako emaitzak lortzeko, Txertaketen Programaren eta Erregistroaren Ponentziak proposatutako \neta Osasun Publikoaren Batzordeak 2017ko urrian adostutako definizioak erabiltzen dira. Ordutik, \nbiztanleriaren jaiotza-kohorteen arabera kalkulatzen dira txertaketa-estaldurak.\n\nEz dira sartzen farmazia-bulegoetan erositako txertoak, ezta osasun-sektore pribatuak emandakoak \nere. \n","texto_oceca":"FUENTE.oceca","justificacion_global":"\nAdierazle honen helburua da txertoen sarbidea neurtzea, horren barruan sartuta oraintsu eskuragarri jarritako txertoak \nedo aski erabiltzen ez direnak, Estatu mailan. \n\nAzken hamarkadetan, herrialde guztiek aski ez erabiltzen diren edo berriak diren txerto ugari gehitu dituzte beren \ntxertaketa-egutegi nazionaletara, eta hainbat txerto daude azken garapen-fasean, 2030era bitartean egutegian sartzeko. \nGaixotasunen kontrola eta txertoen eragina ikuskatzeko, garrantzitsua da txertaketa-egutegi nazionaleko txerto \nbakoitzaren estaldura neurtzea. Programako txerto guztiekin estaltzen den biztanleria-zatia zuzenean neurtzea posible da, \nsoilik baldin eta herrialdeak txertaketen erregistro elektroniko nazionala badu, erregistro horrek ondo funtzionatzen \nbadu, eta kohorteen araberako estaldura aise kalkulatzeko aukera ematen badu. \n\nTxerto hauek neurtzen dira: \n\n- DTP txertoaren estaldura (hirugarren dosia): bizirik iraun zuten eta difteria, tetanos eta kukutxeztularen aurkako \ntxertoaren 3 dosiak urte jakin batean jaso zituzten eta bularreko haurren ehunekoa. \n\n- Elgorriaren aurkako txertoaren estaldura (bigarren dosia): urte jakin batean elgorriaren aurkako bi dosi jaso zituzten \nhaurren ehunekoa, Estatu mailan gomendatutako egutegiaren arabera, errutinazko txertaketa-zerbitzuen bidez. \n\n- Txerto antineumokoziko bateratuaren estaldura (egutegiko azken dosia): bizirik iraun zuten eta Estatu-mailan \ngomendatutako txerto antineumokoziko bateratuaren dosia jaso zuten bularreko haurren ehunekoa, urte jakin batean. \n\n- GPBren aurkako txertoaren estaldura (egutegiko azken dosia): GPBren aurkako txertoaren dosi gomendatuak jaso zituzten \n15 urteko neskatoen ehunekoa. Gaur egun, aurreko egutegiko programaren garapena erabiltzen da, xedeko adin-taldearen \narabera. \n\n\nIturria: Nazio Batuen Estatistika Sekzioa \n","dato_global":"\n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_DTP3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Difteriaren, tetanosaren eta kukutxeztularen aurkako txertoaren (DTP3) 3 dosi jaso dituen xede-biztanleriaren proportzioa (%) SH_ACS_DTP3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_MCV2&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Elgorriaren aurkako txertoaren bigarren dosia jaso duen xede-biztanleriaren proportzioa (MCV2) (%) SH_ACS_MCV2</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_PCV3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Txerto antipneumokoziko konjugatuaren hirugarren dosi bat jaso duen xede-biztanleriaren proportzioa (PCV3) (%) SH_ACS_PCV3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_HPV&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Giza papilomaren birusaren aurkako txertoaren azken dosia jaso duen xede-biztanleriaren proportzioa (%) SH_ACS_HPV</a> UNSTATS \n","comparabilidad":"Eskuragarri dagoen adierazleak Nazio Batuen metadatuak betetzen ditu.","indicador_meta_enlace":"<a href=\"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf\">Metadatuak 3-b-1.pdf</a> (ingelesez bakarrik)","national_data_updated_date":"2025-04-22","national_metadata_updated_date":"2025-06-18","en":{"indicador_disponible":"global_indicators.3-b-1-title","objetivo_global":"objetivo_largo.3-titulo","meta_global":"meta_largo.3-b-titulo","definicion":"Proportion of the target population covered by all vaccines included in their national programme","formula":"\n$$PPV_{\\text{vaccine}}^{t} = \\frac{PV_{\\text{vaccine}}^{\\text{cohort}\\, t - c}}{P^{\\text{cohort}\\, t - c}} \\cdot 100$$\n\nwhere:\n\n$PV_{\\text{vaccine}}^{\\text{cohort}\\, t - c}=$ population vaccinated with the specified type of vaccine, \nbelonging to the cohort born in $t-c$\n\n$P^{\\text{cohort}\\, t - c}=$ total population of the cohort born in $t-c$\n\n${c}=$ interval of years that defines the specific cohort for each vaccine (c=1 or cohort born at t-1 for DPTa and VNC, c=5 for SRP and c=13 for VPH)\n","desagregacion":"Vaccine type: \n- booster vaccination against diphtheria, tetanus, and whooping cough in children (DPTa) \n- booster vaccination against pneumococcus in the pediatric population (VNC)  \n- second dose of the measles, mumps, and rubella vaccine in children (SRP) \n- second dose of the human papillomavirus (HPV) vaccine in adolescents \n\nSex\n","periodicidad":"FUENTE.FREQ_A","observaciones":"\nThe results are obtained using the definitions proposed by the Vaccination Registry and \nProgram Report and agreed by the Public Health Commission in October 2017. Since then, \nvaccination coverage has been calculated by population birth cohorts. \n\nVaccines purchased in pharmacies or administered by the private health sector are not included.\n","texto_oceca":"FUENTE.oceca","justificacion_global":"This indicator aims to measure access to vaccines, including the newly available or \nunderutilized vaccines, at the national level.\n\nIn the past decades all countries added numerous new and underutilised vaccines in \ntheir national immunization schedule and there are several vaccines under final stage of \ndevelopment to be introduced by 2030. For monitoring diseases control and impact of vaccines \nit is important to measure coverage from each vaccine in national immunization schedule. \nDirect measurement for proportion of population covered with all vaccines in the programme \nis only feasible if the country has a wellfunctioning national electronic immunization registry \nallowing coverage by cohort to be easily estimated. \n\nFollowing vaccines are measured:\n\n - Coverage of DTP containing vaccine (3rd dose): Percentage of surviving infants who \nreceived the 3 doses of diphtheria and tetanus toxoid with pertussis containing vaccine \nin a given year.\n\n - Coverage of Measles containing vaccine (2nd dose): Percentage of children who received \ntwo dose of measles containing vaccine according to nationally recommended schedule through \nroutine immunization services in a given year. \n\n - Coverage of Pneumococcal conjugate vaccine (last dose in the schedule): Percentage of \nsurviving infants who received the nationally recommended doses of pneumococcal conjugate \nvaccine in a given year. \n\n - Coverage of HPV vaccine (last dose in the schedule): Percentage of 15 years old girls \nwho received the recommended doses of HPV vaccine. Currently performance of the programme \nin the previous calendar year based on target age group is used. \n\nSource: United Nations Statistics Division\n","dato_global":"\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_DTP3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine (%) SH_ACS_DTP3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_MCV2&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%) SH_ACS_MCV2</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_PCV3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%) SH_ACS_PCV3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_HPV&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\">Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%) SH_ACS_HPV</a> UNSTATS \n","comparabilidad":"The available indicator complies with United Nations metadata.","indicador_meta_enlace":"<a href=\"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf\">Metadata 3-b-1.pdf</a>","informacion_interes":null,"national_data_updated_date":"","national_metadata_updated_date":""},"es":{"indicador_disponible":"global_indicators.3-b-1-title","objetivo_global":"objetivo_largo.3-titulo","meta_global":"meta_largo.3-b-titulo","definicion":"Proporcio\u0301n de la poblacio\u0301n inmunizada con todas las vacunas incluidas en cada programa nacional","formula":"\n$$PPV_{\\text{vacuna}}^{t} = \\frac{PV_{\\text{vacuna}}^{\\text{cohorte}\\, t - c}}{P^{\\text{cohorte}\\, t - c}} \\cdot 100$$\n\ndonde:\n\n$PV_{\\text{vacuna}}^{\\text{cohorte}\\, t - c}=$ es la poblaci\u00f3n vacunada con el tipo de vacuna especificado, \nperteneciente a la cohorte nacida en $t-c$\n\n$P^{\\text{cohorte}\\, t - c}=$ es la poblaci\u00f3n total de la cohorte nacida en $t-c$\n\n${c}=$ el intervalo de a\u00f1os que define la cohorte espec\u00edfica para cada vacuna (c=1 o cohorte nacida en t-1 para DTPa y VNC, c=5 para SRP y c=13 para VPH)\n","desagregacion":"Tipo de vacuna \n","periodicidad":"FUENTE.FREQ_A","observaciones":"\nLos resultados facilitados se obtienen utilizando las definiciones propuestas por la \nPonencia de Programa y Registro de Vacunaciones y acordadas por la Comisi\u00f3n de Salud \nP\u00fablica en octubre de 2017. Desde entonces, las coberturas de vacunaci\u00f3n se calculan \npor cohortes de nacimiento de la poblaci\u00f3n.\n\nNo se incluyen las vacunas adquiridas en oficinas de farmacia ni las \nadministradas por el sector sanitario privado.\n","texto_oceca":"FUENTE.oceca","justificacion_global":"Este indicador tiene por objeto medir el acceso a las vacunas, incluidas las vacunas recientemente \ndisponibles o las que se utilizan de forma insuficiente, a nivel nacional.\n\nEn las \u00faltimas d\u00e9cadas, todos los pa\u00edses \nhan a\u00f1adido numerosas vacunas nuevas y que se utilizan de forma insuficiente a sus calendarios nacionales de \nvacunaci\u00f3n y hay varias vacunas en la fase final de desarrollo que se introducir\u00e1n de aqu\u00ed a 2030. Para supervisar el \ncontrol de enfermedades y el impacto de las vacunas, es importante medir la cobertura de cada vacuna del calendario nacional \nde vacunaci\u00f3n. La medici\u00f3n directa de la proporci\u00f3n de la poblaci\u00f3n cubierta con todas las vacunas del programa solo es posible \nsi el pa\u00eds cuenta con un registro electr\u00f3nico nacional de vacunaci\u00f3n que funcione bien y permita estimar \nf\u00e1cilmente la cobertura por cohorte.\n\nSe miden las siguientes vacunas:\n\n - Cobertura de la vacuna DTP (tercera dosis): porcentaje de lactantes supervivientes que recibieron \nlas 3 dosis de la vacuna contra la difteria, el t\u00e9tanos y la tos ferina en un a\u00f1o determinado.\n\n - Cobertura de la vacuna contra el sarampi\u00f3n (segunda dosis): porcentaje de ni\u00f1os que recibieron dos dosis de la vacuna contra el sarampi\u00f3n seg\u00fan el calendario recomendado a nivel nacional a trav\u00e9s de los servicios de vacunaci\u00f3n de rutina\n en un a\u00f1o determinado.\n\n - Cobertura de la vacuna antineumoc\u00f3cica conjugada (\u00faltima dosis del calendario): porcentaje de lactantes \nsupervivientes que recibieron las dosis de vacuna antineumoc\u00f3cica conjugada recomendadas a nivel nacional en un a\u00f1o determinado.\n\n - Cobertura de la vacuna contra el VPH (\u00faltima dosis del calendario): porcentaje de ni\u00f1as de 15 a\u00f1os que recibieron \nlas dosis recomendadas de la vacuna contra el VPH. Actualmente se utiliza el desempe\u00f1o del programa en el a\u00f1o \ncalendario anterior en funci\u00f3n del grupo de edad objetivo.\n\nFuente: Divisi\u00f3n de Estad\u00edsticas de las Naciones Unidas\n","dato_global":"\n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_DTP3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 3 dosis de la vacuna contra la difteria, el t\u00e9tanos y la tos ferina (DTP3) (%) SH_ACS_DTP3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_MCV2&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 la segunda dosis de la vacuna contra el sarampi\u00f3n (MCV2) (%) SH_ACS_MCV2</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_PCV3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 una tercera dosis de la vacuna antineumoc\u00f3cica conjugada (PCV3) (%) SH_ACS_PCV3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_HPV&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\">Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 la dosis final de la vacuna contra el virus del papiloma humano (VPH) (%) SH_ACS_HPV</a> UNSTATS \n","comparabilidad":"El indicador disponible cumple con los metadatos de Naciones Unidas.","indicador_meta_enlace":"<a href=\"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf\">Metadatos 3-b-1.pdf</a> (solo en ingl\u00e9s)"},"SDG_GOAL__GLOBAL":"<p>Goal 3: Ensure healthy lives and promote well-being for all at all ages</p>","SDG_TARGET__GLOBAL":"<p>Target 3.b: Support the research and development of vaccines and medicines for the communicable and non&#x2011;communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all</p>","SDG_INDICATOR__GLOBAL":"<p>Indicator 3.b.1: Proportion of the target population covered by all vaccines included in their national programme </p>","META_LAST_UPDATE__GLOBAL":"2023-03-31","SDG_RELATED_INDICATORS__GLOBAL":"<p>Target 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all. Indicator 3.8.1: Coverage of essential health services (defined as the average coverage of essential services based on tracer interventions that include reproductive, maternal, newborn and child health, infectious diseases, non-communicable diseases and service capacity and access, among the general and the most disadvantaged population) </p>","SDG_CUSTODIAN_AGENCIES__GLOBAL":"<p>World Health Organization (WHO), United Nations Children&#x2019;s Fund (UNICEF) </p>","CONTACT_ORGANISATION__GLOBAL":"<p>World Health Organization (WHO), United Nations Children&#x2019;s Fund (UNICEF) </p>","STAT_CONC_DEF__GLOBAL":"<p><strong>Definition:</strong> </p>\n<p><em>Coverage of DTP containing vaccine (3<sup>rd</sup> dose):</em> Percentage of surviving infants who received the 3 doses of diphtheria and tetanus toxoid with pertussis containing vaccine in a given year. </p>\n<p> </p>\n<p>Coverage of Measles containing vaccine (2<sup>nd</sup> dose): Percentage of children who received two dose of measles containing vaccine according to nationally recommended schedule through routine immunization services in a given year. </p>\n<p> </p>\n<p>Coverage of Pneumococcal conjugate vaccine (last dose in the schedule): Percentage of surviving infants who received the nationally recommended doses of pneumococcal conjugate vaccine in a given year. </p>\n<p> </p>\n<p>Coverage of HPV vaccine (last dose in the schedule):<strong> </strong>Percentage of 15 years old girls who received the recommended doses of HPV vaccine. Currently performance of the programme in the previous calendar year based on target age group is used. </p>\n<p> </p>\n<p><strong>Concepts:</strong> </p>\n<p>In accordance with its mandate to provide guidance to Member States on health policy matters, WHO provides global vaccine and immunization recommendations for diseases that have an international public health impact. National programmes adapt the recommendations and develop national immunization schedules, based on local disease epidemiology and national health priorities. National immunization schedules and number of recommended vaccines vary between countries, with only DTP polio and measles containing vaccines being used in all countries. </p>\n<p> </p>\n<p>The target population for given vaccine is defined based on recommended age for administration. The primary vaccination series of most vaccines are administered in the first two years of life. </p>\n<p> </p>\n<p><em>Coverage of DTP containing vaccine</em> measure the overall system strength to deliver infant vaccination </p>\n<p>Coverage of Measles containing vaccine ability to deliver vaccines beyond first year of life through routine immunization services. </p>\n<p>Coverage of Pneumococcal conjugate vaccine: adaptation of new vaccines for children </p>\n<p>Coverage of HPV vaccine: life course vaccination<strong> </strong> </p>\n<p> </p>","UNIT_MEASURE__GLOBAL":"<p>Percent</p>","SOURCE_TYPE__GLOBAL":"<p>National Health Information Systems or National Immunization systems </p>\n<p>National immunization registries </p>\n<p>High quality household surveys with immunization module (e.g. Demographic and Health Surveys (DHS), Multiple-Indicator Health Surveys (MICS), other national surveys) </p>","COLL_METHOD__GLOBAL":"<p>Annual data collection through established mechanism. Since 1998, in an effort to strengthen collaboration and minimize the reporting burden, WHO and UNICEF jointly collect information through a standard questionnaire (the Joint Reporting Form) sent to all Member States <a href=\"http://www.who.int/immunization/monitoring_surveillance/routine/reporting/en/\" target=\"_blank\"><u>http://www.who.int/immunization/monitoring_surveillance/routine/reporting/en/</u></a> </p>","FREQ_COLL__GLOBAL":"<p>Annual data collection March-May each year. Country consultation June each year </p>","REL_CAL_POLICY__GLOBAL":"<p>15 July each year for time series 1980 &#x2013; release year -1. (on 17 July 2023 estimates from 1980-2022) </p>","DATA_SOURCE__GLOBAL":"<p>Ministries of Health, Immunization programmes, DHS and MICS websites </p>","COMPILING_ORG__GLOBAL":"<p>WHO and UNICEF</p>","RATIONALE__GLOBAL":"<p>This indicator aims to measure access to vaccines, including the newly available or underutilized vaccines, at the national level. In the past decades all countries added numerous new and underutilised vaccines in their national immunization schedule and there are several vaccines under final stage of development to be introduced by 2030. For monitoring diseases control and impact of vaccines it is important to measure coverage from each vaccine in national immunization schedule. A system is already in place to monitor immunization coverage for all national programmes, however direct measurement for proportion of population covered with all vaccines in the programme is only feasible if the country has a well-functioning national electronic immunization registry allowing coverage by cohort to be easily estimated. While countries will develop and strengthen immunization registries there is a need for an alternative measurement.</p>","REC_USE_LIM__GLOBAL":"<p>The rational to select a set of vaccines reflects the ability of immunization programmes to deliver vaccines over the life cycle and to adapt new vaccines. Coverage for other WHO recommended vaccines are also available and can be provided. </p>\n<p> </p>\n<p>Given that HPV vaccine is relatively new and vaccination schedule varies from countries to country coverage estimate will be made for girls vaccinated by ag 15 and at the moment data is limited to very few countries therefore reporting will start later. </p>","DATA_COMP__GLOBAL":"<p>WHO and UNICEF jointly developed a methodology to estimate national immunization coverage form selected vaccines in 2000, and this approach has been refined and reviewed by expert committees over time. The methodology was published and reference is available under the reference section. Estimates time series for WHO recommended vaccines produced and published annually since 2001. </p>\n<p>The methodology uses data reported by national authorities from countries administrative systems as well as data from immunization or multi indicator household surveys. The WHO/UNICEF estimates of national immunization coverage have been assessed using the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) checklist. </p>","DATA_VALIDATION__GLOBAL":"<p>WHO and UNICEF encourage countries to review and comment on the draft coverage estimates shared following the draft production. In past years, regional or sub-regional consultations have been held during May/June to go through select country data and estimates. </p>","ADJUSTMENT__GLOBAL":"<p>Not applicable</p>","IMPUTATION__GLOBAL":"<ul>\n  <li><strong>At country level </strong></li>\n</ul>\n<p>The first data point is the first reporting year after vaccine introduction. When country data are not available interpolation is used between 2 data points and extrapolation from the latest available data point. </p>\n<ul>\n  <li><strong>At regional and global levels </strong></li>\n</ul>\n<p>Any needed imputation is done at country level. These country values are then used to compute regional and global estimates. </p>","REG_AGG__GLOBAL":"<p>Weighted average of the country-level coverage rates where the weights are the country target population sizes based on World Population Prospects: 2022 revision from the UN Population Division. All Member States from the region are included. For HPV 15 year old girls are used for calculation weighted average. </p>","DOC_METHOD__GLOBAL":"<p>Not applicable</p>","QUALITY_MGMNT__GLOBAL":"<p>Not applicable</p>","QUALITY_ASSURE__GLOBAL":"<p>Not applicable</p>","QUALITY_ASSMNT__GLOBAL":"<p>Not applicable</p>","COVERAGE__GLOBAL":"<p><strong>Data availability:</strong></p>\n<p>Coverage data for different vaccines are collected annually and reviewed by WHO and UNICEF inter agency expert group and estimates made for each country and each year. Data are published both on WHO and UNICEF web sites. </p>\n<p><a href=\"http://www.who.int/immunization/%20monitoring_surveillance/routine/coverage/en/index4.html\" target=\"_blank\"><u>http://www.who.int/immunization/ monitoring_surveillance/routine/coverage/en/index4.html</u></a><u> </u><a href=\"http://www.data.unicef.org/child-health/immunization\" target=\"_blank\"><u>http://www.data.unicef.org/child-health/immunization</u></a> </p>\n<p> </p>\n<p>Coverage for 2021 (in %)</p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>DTP3 </p>\n      </td>\n      <td>\n        <p>MCV2 </p>\n      </td>\n      <td>\n        <p>PCV3 </p>\n      </td>\n      <td>\n        <p>HPV </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Global </p>\n      </td>\n      <td>\n        <p>81</p>\n      </td>\n      <td>\n        <p>71</p>\n      </td>\n      <td>\n        <p>51</p>\n      </td>\n      <td>\n        <p>12</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Australia and New Zealand </p>\n      </td>\n      <td>\n        <p>94</p>\n      </td>\n      <td>\n        <p>92</p>\n      </td>\n      <td>\n        <p>96</p>\n      </td>\n      <td>\n        <p>63</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Central Asia and Southern Asia </p>\n      </td>\n      <td>\n        <p>86</p>\n      </td>\n      <td>\n        <p>83</p>\n      </td>\n      <td>\n        <p>45</p>\n      </td>\n      <td>\n        <p>2</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Eastern Asia and South-eastern Asia </p>\n      </td>\n      <td>\n        <p>84</p>\n      </td>\n      <td>\n        <p>83</p>\n      </td>\n      <td>\n        <p>14</p>\n      </td>\n      <td>\n        <p>1</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Latin America &amp; the Caribbean </p>\n      </td>\n      <td>\n        <p>75</p>\n      </td>\n      <td>\n        <p>68</p>\n      </td>\n      <td>\n        <p>70</p>\n      </td>\n      <td>\n        <p>32</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Northern America and Europe </p>\n      </td>\n      <td>\n        <p>93</p>\n      </td>\n      <td>\n        <p>91</p>\n      </td>\n      <td>\n        <p>80</p>\n      </td>\n      <td>\n        <p>37</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Oceania </p>\n      </td>\n      <td>\n        <p>70</p>\n      </td>\n      <td>\n        <p>63</p>\n      </td>\n      <td>\n        <p>70</p>\n      </td>\n      <td>\n        <p>35</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sub-Saharan Africa </p>\n      </td>\n      <td>\n        <p>70</p>\n      </td>\n      <td>\n        <p>40</p>\n      </td>\n      <td>\n        <p>64</p>\n      </td>\n      <td>\n        <p>20</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Western Asia and Northern Africa (M49) </p>\n      </td>\n      <td>\n        <p>88</p>\n      </td>\n      <td>\n        <p>83</p>\n      </td>\n      <td>\n        <p>56</p>\n      </td>\n      <td>\n        <p>1</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<p> </p>\n<p><strong>Disaggregation:</strong></p>\n<p>Geographical location, i.e. regional and national and potentially subnational estimates </p>","COMPARABILITY__GLOBAL":"<p><strong>Sources of discrepancies:</strong></p>\n<p>Countries often relay on administrative coverage data, while WHO and UNICEF review and assess data from different sources including administrative systems and surveys. Differences between country produced and international estimates are mainly due to differences between coverage estimates from administrative system and survey results. </p>\n<p> </p>\n<p>In case the vaccine is not included in national immunization schedule the coverage from private sector vaccine delivery will not be reflected. </p>","OTHER_DOC__GLOBAL":"<p>Burton A, Monasch R, Lautenbach B, Gacic-Dobo M, Neill M, Karimov R, Wolfson L, Jones G, Birmingham M. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ. 2009;87(7):535-41.Available at: <a href=\"http://www.who.int/bulletin/volumes/87/7/08-053819/en/\" target=\"_blank\"><u>http://www.who.int/bulletin/volumes/87/7/08-053819/en/</u></a> </p>\n<p> </p>\n<p> Burton A, Kowalski R, Gacic-Dobo M, Karimov R, Brown D. A Formal Representation of the WHO and UNICEF Estimates of National Immunization Coverage: A Computational Logic Approach. PLoS ONE 2012;7(10): e47806. doi:10.1371/journal.pone.0047806. Available at: <a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485034/pdf/pone.0047806.pdf\" target=\"_blank\"><u>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485034/pdf/pone.0047806.pdf</u></a> </p>\n<p> </p>\n<p>Brown D, Burton A, Gacic-Dobo M, Karimov R. An Introduction to the Grade of Confidence in the WHO and UNICEF Estimates of National Immunization Coverage. The Open Public Health Journal 2013, 6, 73-76. Available at: <a href=\"http://www.benthamscience.com/open/tophj/articles/V006/73TOPHJ.pdf\" target=\"_blank\"><u>http://www.benthamscience.com/open/tophj/articles/V006/73TOPHJ.pdf</u></a> </p>\n<p> </p>\n<p>Brown, David &amp; Burton, Anthony &amp; Gacic-Dobo, Marta. An examination of a recall bias adjustment applied to survey-based coverage estimates for multi-dose vaccines. 2015. 10.13140/RG.2.1.2086.2883. </p>\n<p>Danovaro-Holliday MC, Gacic-Dobo M, Diallo MS <em>et al.</em> Compliance of WHO and UNICEF estimates of national immunization coverage (WUENIC) with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) criteria. <em>Gates Open Res</em> 2021, 5:77 Available at: <a href=\"https://doi.org/10.12688/gatesopenres.13258.1\">https://doi.org/10.12688/gatesopenres.13258.1</a></p>","target_number":"3.b","goal_number":"3","indicator_sort_order":"03-0b-01"}